Please wait while the formulary information is being retrieved.
QUIT 2 (NICOTINE POLACRILEX)
- Smoking cessation
- Quit 2 Gum
- Quit 2 Buccal Lozenge
- Nicotine (polacrilex) Gum
- Nicorette Gum
- Nicorelief Gum
- By Indication
mg gum
- Chew 1 piece of gum (2 mg) by oral route every 2 hours as needed and as directed
mg buccal lozenge
- 1 tablet (2 mg) dissolved slowly in the mouth by oral route every 8 hours
nicotine (polacrilex) 2 mg gum
- Chew 1 piece of gum (2 mg) by oral route every 2 hours as needed and as directed
nicotine (polacrilex) 4 mg gum
- Chew 1 piece of gum (4 mg) by oral route every 2 hours as needed and as directed
2 mg gum
- Chew 1 piece of gum (2 mg) by oral route every 2 hours as needed and as directed
4 mg gum
- Chew 1 piece of gum (4 mg) by oral route every 2 hours as needed and as directed
2 mg gum
- Chew 1 piece of gum (2 mg) by oral route every 2 hours as needed and as directed
4 mg gum
- Chew 1 piece of gum (4 mg) by oral route every 2 hours as needed and as directed
Smoking cessation
- Chew 1 piece of gum (2 mg) by oral route every hour as needed and as directed
- Chew 1 piece of gum (2 mg) by oral route every 2 hours as needed and as directed
- Chew 1 piece of gum (2 mg) by oral route every 1-2 hours as needed and as directed
- 1 tablet (2 mg) dissolved slowly in the mouth by oral route every hour
- 1 tablet (2 mg) dissolved slowly in the mouth by oral route every 2 hours
- 1 tablet (2 mg) dissolved slowly in the mouth by oral route every hour for 6 weeks
- 1 tablet (2 mg) dissolved slowly in the mouth by oral route every 2 hours for 6 weeks
- 1 tablet (2 mg) dissolved slowly in the mouth by oral route every 1-2 hours
- 1 tablet (2 mg) dissolved slowly in the mouth by oral route every 1-2 hours for 6 weeks
- 1 tablet (2 mg) dissolved slowly in the mouth by oral route every 2-4 hours
- 1 tablet (2 mg) dissolved slowly in the mouth by oral route every 2-4 hours for 3 weeks
- 1 tablet (2 mg) dissolved slowly in the mouth by oral route every 4 hours
- 1 tablet (2 mg) dissolved slowly in the mouth by oral route every 4 hours for 3 weeks
- 1 tablet (2 mg) dissolved slowly in the mouth by oral route every 2 hours for 3 weeks
- 1 tablet (2 mg) dissolved slowly in the mouth by oral route every 8 hours
- 1 tablet (2 mg) dissolved slowly in the mouth by oral route every 8 hours for 3 weeks
- 1 tablet (2 mg) dissolved slowly in the mouth by oral route every 4-8 hours
- 1 tablet (2 mg) dissolved slowly in the mouth by oral route every 4-8 hours for 3 weeks
- None
Contraindicated
- None
Severe
Moderate
- None
- 30 day risk period post-myocardial infarction
- Life-threatening cardiac arrhythmias
- Temporomandibular joint disorder
- Unstable angina pectoris
Contraindicated
- Acute myocardial infarction
- Angina
- Buerger's disease
- Pregnancy
- Prinzmetal angina
- Raynaud's phenomenon
- Severe uncontrolled hypertension
Severe
Moderate
- Disease of liver
- Esophagitis
- Hyperthyroidism
- Peptic ulcer
- Pharyngitis
- Pheochromocytoma
- Type 1 diabetes mellitus
QUIT 2 (NICOTINE POLACRILEX)
- Smoking cessation
- Mouth irritation
- Dysgeusia
- Eructation
- Headache disorder
- Hiccups
- Increased appetite
- Jaw pain
- Nausea
- Sialorrhea
- Sore throat
- Tachycardia
More Frequent
Severe
Less Severe
- Hypertension
- Abdominal pain with cramps
- Aphthous stomatitis
- Constipation
- Dizziness
- Flatulence
- Flushing
- Hoarseness
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Allergic dermatitis
- Angioedema
- Atrial fibrillation
- Cardiac arrhythmia
- Erythema
- Hypersensitivity drug reaction
- Hypertension
- Pruritus of skin
- Seizure disorder
- Skin rash
- Tachycardia
- Urticaria
- Wheezing
Less Severe
- Abdominal pain with cramps
- Acute confusion
- Anorexia
- Arthralgias
- Constipation
- Cough
- Depression
- Diarrhea
- Dizziness
- Drowsy
- Dysgeusia
- Dysmenorrhea
- Edema
- Euphoria
- Flatulence
- Gastric acid hypersecretory conditions
- General weakness
- Headache disorder
- Heartburn
- Hiccups
- Hyperhidrosis
- Hypesthesia
- Insomnia
- Irritability
- Myalgias
- Nausea
- Nervousness
- Nightmares
- Paresthesia
- Sneezing
- Syncope
- Tinnitus
- Vomiting
- Xerostomia
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Nicotine
Use may be considered for adolescents with clinician oversight. Safety and effectiveness not established age <18 years.
- 1 Day – 18 Years
- Use may be considered for adolescents with clinician oversight. Safety and effectiveness not established age <18 years.
Nicotine Polacrilex
- Severity Level:
D
- Additional Notes: Insuff human data; consider risk of continued cig smoking vs. benefit of tx
Contraindicated
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Precaution Exists
Nicotine
Potential for serious adv eff, however benefit of maternal smoking cessation.
General | Excretion Potential | Effect on Infant | Notes |
Evaluate use carefully | Excreted | Not known; no or inclusive data | Potential for serious adv eff, however benefit of maternal smoking cessation. |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
Smoking cessation | |
F17 | Nicotine dependence |
F17.2 | Nicotine dependence |
F17.20 | Nicotine dependence, unspecified |
F17.200 | Nicotine dependence, unspecified, uncomplicated |
F17.201 | Nicotine dependence, unspecified, in remission |
F17.203 | Nicotine dependence unspecified, with withdrawal |
F17.208 | Nicotine dependence, unspecified, with other nicotine-induced disorders |
F17.209 | Nicotine dependence, unspecified, with unspecified nicotine-induced disorders |
F17.21 | Nicotine dependence, cigarettes |
F17.210 | Nicotine dependence, cigarettes, uncomplicated |
F17.211 | Nicotine dependence, cigarettes, in remission |
F17.213 | Nicotine dependence, cigarettes, with withdrawal |
F17.218 | Nicotine dependence, cigarettes, with other nicotine-induced disorders |
F17.219 | Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders |
O99.33 | Tobacco use disorder complicating pregnancy, childbirth, and the puerperium |
O99.330 | Smoking (tobacco) complicating pregnancy, unspecified trimester |
O99.331 | Smoking (tobacco) complicating pregnancy, first trimester |
O99.332 | Smoking (tobacco) complicating pregnancy, second trimester |
O99.333 | Smoking (tobacco) complicating pregnancy, third trimester |
O99.334 | Smoking (tobacco) complicating childbirth |
O99.335 | Smoking (tobacco) complicating the puerperium |
Z87.891 | Personal history of nicotine dependence |
0-9 | A-Z |
---|---|
F17 | Nicotine dependence |
F17.2 | Nicotine dependence |
F17.20 | Nicotine dependence, unspecified |
F17.200 | Nicotine dependence, unspecified, uncomplicated |
F17.201 | Nicotine dependence, unspecified, in remission |
F17.203 | Nicotine dependence unspecified, with withdrawal |
F17.208 | Nicotine dependence, unspecified, with other nicotine-induced disorders |
F17.209 | Nicotine dependence, unspecified, with unspecified nicotine-induced disorders |
F17.21 | Nicotine dependence, cigarettes |
F17.210 | Nicotine dependence, cigarettes, uncomplicated |
F17.211 | Nicotine dependence, cigarettes, in remission |
F17.213 | Nicotine dependence, cigarettes, with withdrawal |
F17.218 | Nicotine dependence, cigarettes, with other nicotine-induced disorders |
F17.219 | Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders |
O99.33 | Tobacco use disorder complicating pregnancy, childbirth, and the puerperium |
O99.330 | Smoking (tobacco) complicating pregnancy, unspecified trimester |
O99.331 | Smoking (tobacco) complicating pregnancy, first trimester |
O99.332 | Smoking (tobacco) complicating pregnancy, second trimester |
O99.333 | Smoking (tobacco) complicating pregnancy, third trimester |
O99.334 | Smoking (tobacco) complicating childbirth |
O99.335 | Smoking (tobacco) complicating the puerperium |
Z87.891 | Personal history of nicotine dependence |
Formulary Reference Tool